Shares of Caribou Biosciences (NASDAQ:CRBU) will be in focus on Friday after the gene-editing biotech announced plans to prioritize its lead oncology clinical programs, CB-010 and CB-011 ...

Caribou Biosciences is winnowing down for the second time in the last year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates.

With heavily muscled bodies, skinny legs, and strong hooves that balloon to the size of dinner plates come winter, mountain caribou — the "mountain ecotype" of the woodland caribou — are well adapted ...

Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued challenges in the cell and gene therapy sector. The company announced on 24 April it is ...